Article Figures & Data
Figures
- FIGURE 1.
Baseline 89Zr-bevacizumab PET images of mRCC patient. (A) Coronal 2-dimensional image through right adrenal gland metastasis, showing additionally 1 local recurrence in left kidney tumor, 1 kidney metastasis, and 1 soft-tissue metastasis near left iliac bone. (B) Sagittal 2-dimensional image through right adrenal gland metastasis, showing additionally 3 kidney metastases and 1 soft-tissue metastasis in abdominal wall.
- FIGURE 2.
Median tumor tracer uptake with interquartile range per patient at baseline (light shading), after 2 wk of everolimus (medium shading), and after 6 wk of treatment (dark shading). Patients in blue stayed on treatment > 12 mo. n = number of quantified tumor lesions per patient.
- FIGURE 3.
(Left) Maximum-intensity projection before treatment showing multiple local recurrences in left kidney tumor and metastases in right kidney, right adrenal gland, and soft-tissue. (Right) Maximum-intensity projection after 6 wk of treatment showing heterogeneous decrease in uptake.
- FIGURE 4.
Tumor tracer uptake before and during treatment. (A) Median uptake and interquartile range for all lesions. (B) Mean tumor uptake per patient. *P < 0.0001.
- FIGURE 5.
Absolute SUVmax change with median for all lesions per patient after 2 wk (light shading) and 6 wk (dark shading) of everolimus treatment. Patients in blue stayed on treatment > 12 mo.
- FIGURE 6.
Plasma VEGF-A concentrations. Each line represents one patient.
Tables
Variable Data Sex Male 9 (69.2) Female 4 (30.8) Age (y) 63 (51–71) Nephrectomy Yes 11 (84.6) No 2 (15.4) Histology Pure clear cell 12 (92.3) Mixed 1 (7.7) World Health Organization performance 0 4 (30.8) 1 2 (15.4) 2 7 (53.8) Tumor sites Number 4 (2–7) Kidney 6 (46.2) Primary 2 (15.4) Local recurrence 2 (15.4) Contralateral 2 (15.4) Lung 9 (69.2) Lymph node 7 (53.8) Bone 6 (46.2) Liver 5 (38.5) Adrenal 4 (30.8) Muscle 4 (30.8) Other 10 (76.9) Previous treatment Tyrosine kinase inhibitor 8 (61.5) Tyrosine kinase inhibitor and interferon alfa ± bevacizumab 2 (15.4) Other 3 (23.1) Qualitative data are expressed as number followed by percentage in parentheses; continuous data are expressed as median followed by range in parentheses.
Supplemental Data
Files in this Data Supplement:
